Objective: Valbenazine (INGREZZA), a novel and highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is FDA-approved for the treatment of tardive dyskinesia (TD) in adults. Because the anatomical distribution and severity of TD can be heterogeneous, Abnormal Involuntary Movement Scale (AIMS) data from a Phase 3 trial of valbenazine (KINECT 3, NCT02274558) were analyzed by body region using shift analyses to assess clinically meaningful improvements in TD.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Parkinsonism & Related Disorders
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2017 Published by Elsevier Inc.